Welcome to our dedicated page for Shattuck Labs news (Ticker: STTK), a resource for investors and traders seeking the latest updates and insights on Shattuck Labs stock.
Shattuck Labs, Inc. (NASDAQ: STTK) is a clinical-stage biotechnology company at the forefront of developing innovative bi-functional fusion proteins. These unique proteins represent a new class of biologic medicine aimed at treating patients with cancer and autoimmune diseases. Shattuck's proprietary Agonist Redirected Checkpoint (ARC®) platform is designed to inhibit checkpoint molecules and activate costimulatory molecules with a single therapeutic, a groundbreaking approach in the biotechnology field.
The company's lead product candidate, SL-172154 (SIRPα-Fc-CD40L), is engineered to block the CD47 immune checkpoint and activate the CD40 pathway simultaneously. Currently, SL-172154 is in multiple Phase 1 clinical trials targeting various cancers, including platinum-resistant ovarian cancer and acute myeloid leukemia (AML). Another promising candidate, SL-279252 (PD1-Fc-OX40L), is being developed in collaboration with Takeda Pharmaceuticals and is also in Phase 1 trials.
Shattuck Labs recently embarked on an exciting collaboration with Ono Pharmaceutical to develop bifunctional fusion proteins for autoimmune and inflammatory diseases. This partnership includes a significant financial package with potential milestone payments and royalties, reinforcing Shattuck's strong financial condition and innovative capabilities. Additionally, the company's proprietary gamma delta T cell engager platform, GADLEN™, promises to bridge gamma delta T cells to tumor antigens, offering new hope for cancer treatment.
Recent achievements include rapid enrollment in clinical trials and the FDA's orphan drug designation for SL-172154, highlighting the urgent need for new AML treatments. Shattuck is also actively participating in several high-profile conferences, sharing their latest research and clinical progress. The company is headquartered in Austin, Texas, and Durham, North Carolina, and continues to leverage its scientific expertise to address unmet medical needs.
- Core Business: Development of bi-functional fusion proteins for cancer and autoimmune diseases.
- Recent Achievements: FDA orphan drug designation for SL-172154, collaboration with Ono Pharmaceutical.
- Current Projects: Phase 1 trials for SL-172154 and SL-279252, development of GADLEN™ platform.
- Financial Condition: Strong financial backing with potential milestone payments from partnerships.
- Partnerships: Collaborations with Ono Pharmaceutical and Takeda Pharmaceuticals.
Shattuck Labs, Inc. (NASDAQ: STTK), a biotechnology company, will host a live webcast on November 12, 2021, at 8:00 a.m. ET, to present clinical data from ongoing Phase 1 trials. The event features CEO Taylor Schreiber along with other executives discussing their lead bi-functional fusion proteins. Highlights include data for SL-172154 in ovarian cancer and SL-279252 in solid tumors and lymphoma. The presentation will be accessible via conference call and archived online for 90 days.
Austin-based Shattuck Labs (STTK) is a clinical-stage biotechnology company focused on bi-functional fusion proteins for treating cancer and autoimmune diseases. They have three ongoing Phase 1 clinical trials and announced participation in four upcoming virtual investor conferences this November. Key presentations include the Berenberg US CEO Conference on November 10 and the Cowen IO Next Summit on November 15, featuring CEO Taylor Schreiber. A live webcast of these events will be available on their website, with replays archived for 90 days.
Shattuck Labs (NASDAQ: STTK) has appointed Dr. Carrie Brownstein as a new Board member, succeeding Josiah Hornblower, the founder and former Chairman. Dr. Brownstein brings extensive experience from her role as Chief Medical Officer at Cellectis and past positions at major pharmaceutical companies. George Golumbeski, Ph.D., has been appointed as the new Chairman of the Board. This management change is expected to enhance Shattuck's strategic growth as it advances its clinical programs, particularly the SL-172154 candidate.
Shattuck Labs (NASDAQ: STTK) announced it will present four posters at the SITC’s 36th Annual Meeting from November 10-14, 2021. The presentations will cover key studies, including a Phase 1 trial of SL-172154 for platinum-resistant ovarian cancer and SL-279252 for advanced solid tumors. The company's proprietary Agonist Redirected Checkpoint (ARC®) platform aims to enhance cancer treatment by simultaneously blocking immune checkpoints and activating costimulatory pathways. These presentations highlight Shattuck's ongoing commitment to innovative cancer therapies.
Shattuck Labs, Inc. (NASDAQ: STTK), a clinical-stage biotech firm, announced its participation in three virtual investor conferences in September 2021. CEO Taylor Schreiber will lead discussions at the Citi 16th Annual BioPharma Virtual Conference on September 9, the H.C. Wainwright 23rd Annual Global Investment Conference on September 13, and the Morgan Stanley 19th Annual Global Healthcare Conference on September 15. The company's innovative therapies focus on cancer and autoimmune diseases, including lead programs evaluated in Phase 1 trials.
Shattuck Labs (NASDAQ: STTK) announced the submission of abstracts for Phase 1 dose-escalation data on SL-172154 and SL-279252, to be presented at the SITC Annual Meeting in November 2021. Initial safety data for SL-172154 in ovarian cancer shows an encouraging profile, with plans to expand its study to AML and HR-MDS by Q4 2021. The company reported a net loss of $23.6 million for Q2 2021, an increase from $6.2 million in 2020, while cash reserves of $304.8 million are expected to support operations through 2024.
Shattuck Labs, Inc. (NASDAQ: STTK), a clinical-stage biotechnology firm, will participate in the BTIG Biotechnology Conference on August 10, 2021. The event will feature a fireside chat with CEO Taylor Schreiber, CMO Lini Pandite, and CFO Andrew Neill at 1:30 p.m. EST. Shattuck focuses on developing bi-functional fusion proteins targeting cancer and autoimmune diseases, with its lead program, SL-172154, currently in a Phase 1 trial. Another compound, SL-279252, is in Phase 1 trials in collaboration with Takeda Pharmaceuticals.
Shattuck Labs, Inc. (NASDAQ: STTK), a clinical-stage biotechnology company, is set to provide a corporate and financial update for Q2 2021 on August 11, 2021, at 4:30 p.m. ET. The earnings call can be accessed via phone and will be available in archived format for up to 90 days afterward. Shattuck focuses on bi-functional fusion proteins to treat cancer and autoimmune diseases, with lead programs SL-172154 and SL-279252 currently in Phase 1 trials. The company leverages its proprietary ARC® platform for innovative therapies.
Shattuck Labs (NASDAQ: STTK) announced the appointment of Abhinav A. Shukla, Ph.D., as Chief Technical Officer. His extensive experience in biologics manufacturing and gene therapy is expected to enhance the company's capabilities in developing its ARC and GADLEN platform compounds. Dr. Shukla previously held senior positions at Redpin Therapeutics and CRISPR Therapeutics, contributing to numerous investigational new drug applications and commercialized therapeutics. Shattuck aims to advance its bi-functional fusion proteins targeting cancer and autoimmune diseases through its innovative platforms.
Shattuck Labs (NASDAQ: STTK) reported Q1 2021 financial results, showing a net loss of $11.8 million, or $0.28 per share, compared to a $6.6 million loss in Q1 2020. Cash and equivalents totaled $321.2 million as of March 31. The company is on track for initial dose-escalation data from its clinical trials of CD47 inhibitor SL-172154 and PD-1 inhibitor SL-279252 in the second half of 2021. R&D expenses rose to $10.3 million, reflecting ongoing clinical developments. Financial guidance indicates sufficient funds to support operations through 2024.
FAQ
What is the current stock price of Shattuck Labs (STTK)?
What is the market cap of Shattuck Labs (STTK)?
What is Shattuck Labs, Inc.'s core business?
What are the main product candidates of Shattuck Labs?
What is the ARC® platform?
Who are Shattuck Labs' key partners?
Where is Shattuck Labs headquartered?
What is SL-172154?
What recent achievements has Shattuck Labs made?
What is the GADLEN™ platform?
What financial condition is Shattuck Labs in?
What are some upcoming events for Shattuck Labs?
